New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
09:28 EDTHSH, JKS, FRO, ARO, SDRL, BCRX, PFE, AZN, PF, PPC, SPLSOn The Fly: Pre-market Movers
HIGHER: Pilgrim's Pride (PPC), up 5% after proposing to acquire Hillshire Brands (HSH) for $45.00 per share cash. Hillshire up 21% following the news, while Pinnacle Foods (PF), which has agreed to be acquired by Hillshire, is down 6.4%... BioCryst (BCRX), up 19% after announcing "positive" results from OPuS-1, a trial of BCX4161... Seadrill (SDRL), up 2.6% after signing investment and cooperation pact with Rosneft and North Atlantic... Aeropostale (ARO), up 11% after $150M financing transaction with Sycamore. LOWER: AstraZeneca (AZN), down 1.7% after downgraded at Societe Generale following Pfizer (PFE) confirming it won't bid for AstraZeneca after rejection of proposal. Pfizer shares are up 1% after the news... Staples (SPLS), down 1% after downgraded at Goldman... Frontline (FRO), down 7.4% after saying it sees weaker Q2 operational results... JinkoSolar (JKS), down 7.8% after reporting lower than expected Q1 earnings results.
News For HSH;PPC;PF;AZN;PFE;BCRX;SDRL;ARO;FRO;JKS;SPLS From The Last 14 Days
Check below for free stories on HSH;PPC;PF;AZN;PFE;BCRX;SDRL;ARO;FRO;JKS;SPLS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 21, 2014
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
09:07 EDTSPLSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: PetSmart (PETM), up 2,1%... Staples (SPLS), up 2%... E-House (EJ), up 2.5%. HIGHER: Fairchild (FCS), up 4% after Bloomberg says Infineon (IFNNY) is near a deal to buy a U.S. semiconductor company for $2B... Amicus Therapeutics (FOLD), up 18.4% after reporting positive Phase 3 data from the Fabry study. DOWN AFTER EARNINGS: Lowe's (LOW), down 3%... Tarena (TEDU), down 9%... Leju (LEJU), down 4.2%... JA Solar (JASO), down 5%. LOWER: Hertz (HTZ), down 12.7% after downgraded at JPMorgan and Deutsche Bank following the company's decision to withdraw its FY14 guidance... NovaBay (NBY), down 35.2% after primary, secondary endpoints were not met in its NVC-422 study... RGS Energy (RGSE), down 14.9% after downgraded at Roth Capital following Q2 earnings results.
08:03 EDTPFEBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
07:05 EDTJKSJinkoSolar to supply 40 MW of PV Solar Modules to Chilean solar company
Subscribe for More Information
06:06 EDTSPLSStaples expects to record pre-tax restructuring charges of $40M-$75M in Q3
For the full year, the company expects total pre-tax restructuring and other related charges in the range of $230M-$310M. For the full year, the company expects to generate more than $600Mof free cash flow. The company’s free cash flow guidance reflects an expected use of cash in the range of $60M-$100M associated with its 2014 restructuring plan, as well an expected use of cash in the range of $50M-$100M related to its 2012 and 2013 restructuring plans.
06:05 EDTSPLSStaples sees Q3 non-GAAP EPS 34c-39c, consensus 37c
Subscribe for More Information
06:04 EDTSPLSStaples reports Q2 North American Commercial sales up 2.6% to $2.0B
Reports Q2 International Operations sales $941M.
06:04 EDTSPLSStaples reports Q2 SSS excluding Staples.com down 5%
Subscribe for More Information
06:03 EDTSPLSStaples secured $150M of annualized cost savings in year-to-date
The savings is part of a two year plan to eliminate at least $500M of annualized costs. The company closed 80 stores in North America during Q2 and expects to close approximately 140 store sin North America during 2014.
06:01 EDTSPLSStaples reports Q2 non-GAAP EPS 12c, consensus 11c
Reports Q2 revenue $5.22B, consensus $5.16B
August 19, 2014
18:19 EDTHSHTyson, Hillshire announce extension of tender offer for shares of Hillshire
Subscribe for More Information
15:16 EDTSPLSNotable companies reporting before tomorrow's open
Subscribe for More Information
15:06 EDTSPLSStaples technical comments before earnings
Subscribe for More Information
15:01 EDTSPLSStaples September volatility flat into Q2 and guidance
Staples September call option implied volatility is at 32, December is at 30; compared to its 26-week average of 32 according to Track Data, suggesting non-directional price movement into the expected release of Q2 results on August 20.
11:53 EDTAROAeropostale soars as Geiger returns as CEO
Subscribe for More Information
10:49 EDTAROAeropostale breaks out as Geiger returns as CEO
The $3.50 level has been the top of the trading range, a base, since June of this year. With price currently at $3.80, the shares have bullishly broken out of the range. Longer base breakouts typically persist for some time following the break. At current price next resistance is at $3.98. Support is at $3.50. For the breakout to remain valid, share price needs to close today well above that $3.50 mark.
09:20 EDTJKSReported settlement offer positive for Chinese solar stocks, says Roth Capital
Subscribe for More Information
09:07 EDTAROOn The Fly: Pre-market Movers
Subscribe for More Information
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
06:56 EDTAROAeropostale CEO change may not help much, says Wells Fargo
After Aeropostale announced that its longtime former CEO, Julian Geiger, would return to the role, Wells Fargo thinks that Geiger may not be able to solve the company's positioning problems. According to the firm, the company was known for providing basics, but consumers are not willing to pay for basics anymore. The firm keeps a Market Perform rating on the shares.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use